Clinical Trial Update: Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study evaluating a synthetic vaccine targeting the HIV Tat protein in seropositive patients with AIDS.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome

Drugs mentioned

• Tat protein-targeting HIV vaccine

Snippet

Sponsor: BIOSANTECH | Conditions: AIDS | Phase 1, Phase 2 | Status: UNKNOWN